Medytox Affiliate Newmeco Launches Next-Generation Toxin 'Newlux'

Exclusion of Animal-Derived Ingredients in Production Process
All Shipments for This Month Fully Pre-Ordered
Overseas Exports to Begin in Second Half of Next Year

Medytox announced on the 13th that its affiliate Newmeco has launched the next-generation botulinum toxin (BTX) product 'NEWLUX'.

Next-generation toxin formulation 'NEWLUX' by Newmeco, a Medytox affiliate.
[Photo by Newmeco]

NEWLUX, which Newmeco obtained product approval for from the Ministry of Food and Drug Safety in August, is a next-generation BTX formulation that excludes animal-derived ingredients during the raw material production process, fundamentally eliminating the possibility of allergic reactions caused by animal antigens.

Additionally, by reducing chemical processing steps, it minimizes the denaturation of the active neurotoxin protein and reduces side effects that may occur after procedures due to chemical contamination. Furthermore, recognizing that allergic reactions can be triggered by human serum albumin, NEWLUX is the first 900kDa (kilodalton) BTX product to apply a process excluding animal-derived ingredients. Through this, Newmeco explains that it is expected to meet market expectations for high efficacy and safety.

Newmeco emphasized that even before its launch, inquiries continued, and all shipment volumes for this month were pre-ordered. The company aims to become the number one domestic toxin product in a short period through mass supply, as NEWLUX is being produced at Medytox’s Plant 3.

At the same time, a customized market entry strategy by country has been established, and overseas exports are planned to be fully launched from the second half of next year. Medytox plans to enter the Chinese market with NEWLUX. To this end, it withdrew the import drug registration application for Meditoxin (export name Neuronox), which was submitted to the China National Medical Products Administration (NMPA) in 2018. Considering the growth potential of the Chinese market, the decision was made based on the judgment that entering China with NEWLUX, which has a complete mass production system and applies the latest manufacturing processes, is better than the previous plan.

Joo Hee-seok, CEO of Newmeco, said, "Market interest in NEWLUX is hot, with all production for this month sold out through pre-orders even before launch," and added, "We are focusing on expanding production volume to continue the NEWLUX surge, and I am confident that it will soon become the number one toxin product domestically." CEO Joo also emphasized, "Based on Newmeco’s strong sales and marketing capabilities, we will demonstrate overwhelming competitiveness in the market."

Meanwhile, with the launch of NEWLUX by its affiliate Newmeco, Medytox has uniquely established a portfolio of four toxin products worldwide, including the existing three BTX products: Meditoxin, Coretox, and Innotox.

This content was produced with the assistance of AI translation services.